Korsana Biosciences, Inc. Common Stock
KRSA
51 hedge funds and large institutions have $40.7M invested in Korsana Biosciences, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 17 closing their positions.
553% more call options, than puts
Call options by funds: $705K | Put options by funds: $108K
2.42% less ownership
Funds ownership: 57.05% → 54.63% (-2.4%)
12% less funds holding
Funds holding: 58 → 51 (-7)
23% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 13
35% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 17
46% less capital invested
Capital invested by funds: $75.8M → $40.7M (-$35.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$148K |
| 2 |
PVI
Pura Vida Investments
New York
|
+$118K |
| 3 |
Renaissance Technologies
New York
|
+$92.3K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$84.3K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$25.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$4.93M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$280K |
| 3 |
VF
Virtu Financial
New York
|
-$170K |
| 4 |
JF
Jump Financial
Chicago,
Illinois
|
-$160K |
| 5 |
Goldman Sachs
New York
|
-$135K |
KRSA Hedge Fund Activity: Q4 2021 in Review
51 of the 6,519 institutional investors tracked by Wall St. Rank reported a position in Korsana Biosciences, Inc. Common Stock (KRSA) for Q4 2021, worth a combined $40.7M — down 46% from $75.8M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of KRSA and 11 opened new positions — a net loss of 6 holders — while 13 trimmed existing stakes and 10 added.
The largest buyer was Vanguard Group, adding an estimated $148K. The largest seller was EcoR1 Capital, exiting entirely with an estimated $4.93M sold.
- 51 institutional investors held Korsana Biosciences, Inc. Common Stock (KRSA) as of Q4 2021, down from 58 in Q3 2021.
- Funds reported $40.7M of Korsana Biosciences, Inc. Common Stock stock for Q4 2021, down 46% quarter-over-quarter.
- 11 funds opened new Korsana Biosciences, Inc. Common Stock positions in Q4 2021 and 17 closed out, a net change of -6 holders.
- The largest Korsana Biosciences, Inc. Common Stock buyer in Q4 2021 was Vanguard Group, an estimated $148K added.
- The largest Korsana Biosciences, Inc. Common Stock seller in Q4 2021 was EcoR1 Capital, an estimated $4.93M sold.
Based on aggregated 13F filings for Q4 2021.